NCT01073436终止不适用
Discontinuation of Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myeloid Leukemia, Previously Treated With Interferon-Alpha
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Relapse-free survival
研究概览
简要总结
To investigate whether patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecular remission, are able to discontinue therapy and maintain a durable remission. Relapse-free survival (RFS) rate at 1 year after discontinuation of TKI will be the measurement of this objective.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a diagnosis of Philadelphia chromosome positive (Ph+) chronic myeloid leukemia in chronic phase.
- •Patients must have received prior therapy with interferon-alpha for their CML, for a period of at least 2 years, and achieved at least a partial cytogenetic response on this therapy, defined as 1% - 34% Ph+ cells in metaphase, present in the bone marrow.
- •Patients must be actively receiving treatment for their CML with a TKI (imatinib mesylate, dasatinib, nilotinib). If patients are receiving dasatinib or nilotinib, this can only be for reasons other than imatinib-resistant CML.
- •Patients must have an ongoing complete hematologic response (CHR) on a TKI, defined as follows:
- •WBC ≤ 10 x 109/L.
- •Platelet count < 450,000 x 109/L.
- •No blasts or promyelocytes in peripheral blood.
- •No evidence of disease-related symptoms and extramedullary disease, including the liver and spleen.
- •Patients must have a complete cytogenetic response (CCyR) on a TKI for a minimum of one year leading up to enrollment. Complete cytogenetic response is defined as 0% Ph+ cells in metaphase, in the bone marrow and/or a negative peripheral blood FISH analysis for the BCR/ABL gene fusion, and an ongoing CCyR must be confirmed by bone marrow aspirate cytogenetics and/or peripheral blood FISH for BCR/ABL within 4 weeks of discontinuing therapy.
- •Patients must have at least a major molecular remission on a TKI for a minimum of 1 year, present on 2 consecutive analyses, performed at least 3 months apart, in the 6 to 12 months leading up to enrollment. Major molecular remission is defined as ≥ 3 log reduction from a standard baseline value (equivalent to a BCR-ABL/ABL of ≤ 0.1%) in BCR/ABL transcript by quantitative RT-PCR performed on peripheral blood or bone marrow aspirate. Complete molecular remission is defined as a negative quantitative RT-PCR (QPCR) analysis for BCR/ABL, present on 2 consecutive analyses, performed at least 3 months apart, in the 6 to 12 months leading up to enrollment.
- •Patients must be eighteen years of age or older
- •Patients must have an ECOG performance status of 0-2 (Appendix 13.1)
- •All patients must be informed of the investigational nature of this study and standard alternative therapy. All patients must sign and give written informed consent in accordance with institutional and federal guidelines.
排除标准
- •Patients who have had prior progression of their CML to accelerated phase or blast crisis.
- •Patients who have previously undergone hematopoietic stem cell transplantation.
- •Patients receiving dasatinib or nilotinib due to a prior history of imatinib-resistant CML.
- •Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable.
结局指标
主要结局
Relapse-free survival
时间窗: 1 year
Relapse-free survival (RFS) rate at 1 year after discontinuation of TKI will be the measurement of this objective.
次要结局
- Reduction of the malignant stem cell population(1 Year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
A Study for Tyrosine Kinase Inhibitors DiscontinuationLeukemiaNCT02897245Versailles Hospital200
已完成
不适用
Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.Chronic Myeloid LeukemiaTyrosine Kinase InhibitorWithdrawal SyndromeNCT03996096University Hospital, Caen50
Unknown
不适用
To Study the Impact of Stopping Therapy in Patients of CML With Molecular RemissionChronic Myeloid LeukemiaTreatment Free RemissionNCT03062436Command Hospital, India27
已完成
2 期
Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs TherapyMyelogenousChronicBCR-ABL PositiveLeukemiaNCT02638467University of Milano Bicocca2
Unknown
2 期
Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI TreatmentCML, RelapsedNCT03573596Amsterdam UMC, location VUmc134